In addition, the authors would like to caution physicians that this case report also raises the possibility of hypothermia developing in patients receiving risperidone irrespective of the duration that they take the medication and to

emphasize the importance of educating the treating physicians as well as the patients and their family with regards to the identification and remedy of this sinister adverse effect of risperidone. Inhibitors,research,lifescience,medical Footnotes Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest statement: The author declares that there is no conflict of interest. Contributor Information M. A. Lasitha Perera, General Psychiatry, National Institute of Mental Health, Sri Lanka. Jegan Yogaratnam, General Psychiatry, National Institute of Mental Health, Angoda, Sri Lanka.
Studies have unequivocally documented the occurrence of a cannabis dependence syndrome by demonstrating Inhibitors,research,lifescience,medical that cannabis has reinforcing selleck chemical properties in nonhuman primates and that abstinence from the drug causes withdrawal in humans [Tanda and Goldberg, 2003; Fattore et al. 2008]. This withdrawal syndrome can last from 1 to 3 weeks after cannabis cessation [Budney and Hughes, 2006]. The risk of relapse after a period of abstinence is significant [Perkonigg Inhibitors,research,lifescience,medical et al. 2008]. Haney and colleagues have demonstrated that Oral Delta-9-THC

seemed to ameliorate substantially symptoms of cannabis withdrawal and could decrease physiological and subjective effects of cannabis withdrawal [Haney et al. 2010]. Other treatments such as clonidine and rimonabant have also been demonstrated to decrease physiological and subjective effects, but none of these treatments have been successful in Inhibitors,research,lifescience,medical treating cannabis dependence or self-administration behavior [Hart, 2005]. Clinical studies have examined several treatment options and despite their limitations, they have suggested that treating cannabis withdrawal can improve the likelihood of prolonged abstinence [Clapper et al. 2009]. Nevertheless there is currently no recognized pharmacological

Inhibitors,research,lifescience,medical treatment for the management of withdrawal syndrome or relapse prevention in cannabis dependent patients and clinical research with GABA-B compounds is warranted given this important objective as stated by Vandrey and Haney [Vandrey and Haney, 2009]. Baclofen, a selective GABA-B Clinical Microbiology Reviews agonist, has already been studied for alcohol and cocaine withdrawal and relapse prevention [Addolorato et al. 2006; Shoptaw et al. 2003]. Its safety and tolerability have been confirmed in several studies [Addolorato et al. 2002; Stallings and Schrader, 2007] and the low potential for abuse of baclofen must be regarded as a major factor in pharmacological treatment of substance addiction [Addolorato et al. 2000]. Few data are available today regarding the use of baclofen in the treatment of cannabis dependence.